AIL DILI B1 common mistakes
AIL DILI B1 · Understand the traps and how to avoid them.
Classifying every leukaemia by speed alone (acute vs chronic) and then stopping, without assigning the myeloid or lymphoid lineage, so a question asking for the specific type gets an incomplete answer.
Candidates learn 'acute = blasts, chronic = mature cells' first and treat that single axis as the whole classification, forgetting the second myeloid/lymphoid axis.
What to do instead
For every leukaemia case, state both axes explicitly: tempo (acute vs chronic) and lineage (myeloid vs lymphoid), then add the defining cell feature (e.g. Auer rods point to myeloid, lymphoblasts lack them).
Labelling any leukaemia with a very high white cell count and immature cells as acute leukaemia, when the marrow picture and clinical course fit a chronic phase.
The high blast-like count dominates attention, and candidates anchor on the number rather than on the maturation pattern and the patient's tempo of illness.
What to do instead
Judge acute vs chronic from the degree of maturation and the clinical time course, not from the total white count; ask whether mature forms are present alongside the immature ones.
Confusing the typical age group and cell marker profile of acute lymphoblastic leukaemia with acute myeloid leukaemia, then picking the wrong immunophenotype or the wrong expected age.
Both are 'acute leukaemias' and share blast morphology, so the distinguishing markers and age peaks blur together in memory.
What to do instead
Anchor ALL to childhood peak and B/T lymphoid markers, AML to adult peak and myeloid markers plus Auer rods; rehearse one paired contrast table rather than each disease separately.
Missing the leukaemic transformation of a chronic myeloproliferative disorder, answering only with the original chronic disease when the question describes sudden blasts and worsening counts.
Candidates recognise the chronic disorder from earlier in the stem and stop reading, ignoring the new blast phase described at the end.
What to do instead
Read the full stem for a change in tempo; if blasts appear in a known chronic myeloid disorder, answer with the transformed (blast) phase, not the chronic diagnosis.
Describing Hodgkin lymphoma and non-Hodgkin lymphoma with the same cell of origin and spread pattern, so a question on Reed-Sternberg cells or contiguous spread is answered with non-Hodgkin features.
Both are lymphomas and share lymphadenopathy, and candidates memorise 'lymphoma' as one concept without separating the two families.
What to do instead
Fix two contrast anchors: Hodgkin = Reed-Sternberg cells, contiguous nodal spread, B symptoms prominent; non-Hodgkin = heterogeneous lymphoid cells, often non-contiguous or extranodal spread.
Treating 'B symptoms' as any symptom the patient reports, or omitting them, instead of applying the specific triad when staging or describing lymphoma.
The label 'B symptoms' sounds generic, so candidates either count unrelated complaints or forget the triad entirely.
What to do instead
Memorise the triad explicitly (unexplained fever, drenching night sweats, significant weight loss) and use only those three when the question asks about B symptoms or staging.
Assigning a lymphoma to the wrong aggressiveness category (indolent vs aggressive) based on the patient's age or nodal size rather than on the histological subtype.
Clinical features feel more concrete than histology, so candidates infer behaviour from the patient rather than from the named subtype.
What to do instead
Link each named subtype to its behaviour (e.g. follicular and small lymphocytic as indolent; diffuse large B-cell and Burkitt as aggressive) and answer from the subtype name first.
Confusing the diagnostic criteria and clinical picture of multiple myeloma with those of other plasma cell or lymphoproliferative disorders, so a case with bone pain and renal failure is mislabelled.
Plasma cell disorders overlap in paraprotein findings, and candidates latch onto 'abnormal protein' without checking the full myeloma-defining features.
What to do instead
Apply the myeloma-defining constellation deliberately: clonal plasma cells, monoclonal protein, and end-organ damage (calcium, renal, anaemia, bone lesions), rather than any single abnormal result.
Interpreting a monoclonal protein as automatically diagnostic of multiple myeloma, ignoring that it can occur in benign or premalignant plasma cell conditions.
The paraprotein is the most memorable finding, so candidates treat its presence as sufficient and skip the distinction between monoclonal gammopathy of undetermined significance, smouldering, and active myeloma.
What to do instead
Always ask whether end-organ damage or myeloma-defining events are present; without them, consider premalignant or undetermined significance rather than active myeloma.
Mixing up the typical laboratory and radiological findings of myeloma (e.g. lytic bone lesions versus sclerotic, or the pattern of anaemia and hypercalcaemia) with those of other malignancies that spread to bone.
Bone involvement and anaemia appear in many cancers, and candidates carry over findings from solid tumours or lymphoma without checking the myeloma-specific pattern.
What to do instead
Memorise the myeloma signature as lytic (not sclerotic) lesions, normocytic anaemia, hypercalcaemia and renal impairment, and check each finding against that signature before choosing.